Aligos Therapeutics grants options to officer Calhoun

Aligos Therapeutics, Inc. reported a compensation-related stock option grant to officer Lesley Ann Calhoun.

Rhea-AI Filing Summary

Aligos Therapeutics, Inc. reported a compensation-related stock option grant to officer Lesley Ann Calhoun. She was awarded options to acquire 37,485 shares of common stock at an exercise price of $7.03 per share, expiring on March 9, 2036.

According to the vesting terms, 1/48th of the options vest in equal monthly installments starting on March 9, 2026, so the grant becomes fully vested and exercisable on the fourth anniversary of that date, subject to her continued service. This filing reflects an acquisition of derivative securities, not an open-market purchase or sale of common shares.

Insider Trade Summary

Grant/Award: 37,485 shares

Grant/Award 1 txn

Insider Calhoun Lesley Ann

Role See Remarks

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	37,485	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 37,485 contracts (Direct)

Footnotes (1)

1. F1. 1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from March 9, 2026 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Aligos Therapeutics (ALGS) report for Lesley Ann Calhoun?

Aligos Therapeutics reported a grant of stock options to officer Lesley Ann Calhoun. She received options for 37,485 shares of common stock at an exercise price of $7.03 per share, expiring on March 9, 2036, as part of her compensation.

Is the Aligos Therapeutics (ALGS) Form 4 transaction a buy or a sale?

The Form 4 shows an acquisition through a stock option grant, not a market trade. The transaction code is “A,” meaning a grant or award, so there is no open-market buying or selling of common shares in this filing.

What is the vesting schedule for the Aligos Therapeutics (ALGS) options granted to Calhoun?

The options vest over four years, starting on March 9, 2026. One forty-eighth of the total options vests monthly, so 100% of the 37,485 options become fully vested and exercisable on the fourth anniversary, contingent on continued service.

How many Aligos Therapeutics (ALGS) options does Lesley Ann Calhoun hold after this Form 4?

After this reported grant, Lesley Ann Calhoun holds 37,485 stock options linked to Aligos Therapeutics common shares. This entire amount comes from the new award disclosed and represents derivative securities rather than currently owned common stock.

What does the exercise price on the Aligos Therapeutics (ALGS) option grant mean?

The exercise price of $7.03 per share is the cost to buy each Aligos Therapeutics common share under the option. Calhoun can choose to exercise vested options at this price any time before the expiration date of March 9, 2036.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/11/2026 - 04:13 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Calhoun Lesley Ann

(Last) (First) (Middle)

C/O ALIGOS THERAPEUTICS, INC.

1 CORPORATE DRIVE, 2ND FLOOR

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Aligos Therapeutics, Inc. [ ALGS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
03/09/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$7.03	03/09/2026		A		37,485		(1)	03/09/2036	Common Stock	37,485	$0	37,485	D

Explanation of Responses:

1. 1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from March 9, 2026 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.

Remarks:

Chief Operating Officer and Chief Financial Officer

	/s/ Lesley Ann Calhoun	03/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.